Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2014

Open Access 01-12-2014 | Study protocol

Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarction: study protocol for a randomized controlled trial

Authors: Nima Rudd, Ivan Subiakto, Muhammad Asrar ul Haq, Vivek Mutha, William J Van Gaal

Published in: Trials | Issue 1/2014

Login to get access

Abstract

Background

The incidence of perioperative myocardial infarction (PMI) globally is known to be around 2 to 3% and can prolong hospitalization, increased morbidity and mortality. Little is known about the pathophysiology and risk factors for PMI. We investigate the presence of elevated novel cardiac markers and preoperative coronary artery plaque through contemporary laboratory techniques to determine the correlation with PMI, as well as studying ivabradine and atorvastatin as protective pharmacotherapies against PMI in the context of orthopedic surgery.

Methods/Design

We aim to enroll 200 patients aged above 60 years who suffer from neck of femur fracture requiring surgery. Patients will be randomized to four arms (no study drugs, atorvastatin only, ivabradine only and ivabradine and atorvastatin). Our primary outcome is incidence of PMI. All patients will receive an electrocardiogram, cardiac echocardiography, measurement of novel cardiac biomarkers and computed tomography (CT) coronary angiography. A telephone interview post discharge will be conducted at 30 days, 60 days and 1 year.

Discussion

We postulate that ivabradine and atorvastatin will reduce the rate and magnitude of PMI following surgery by reducing heart rate and attenuating catecholamine-induced tachycardia postoperatively. Secondly, we postulate that postoperative reduction in heart rate and catecholamine-induced tachycardia with ivabradine will correlate with a reduction in cardiovascular novel biomarkers which will reduce atrial stretch and postoperative incidence of arrhythmia. We aim to demonstrate that treatment with ivabradine and atorvastatin will cause a reduction in the incidence and magnitude of PMI, the benefit of which is derived primarily in patients with greater atherosclerotic burden as measured by higher CT coronary calcium scores.

Trial registration

This study protocol has been listed in the Australia New Zealand Clinical Trial Registry (registration number: ACTRN12612000340​831) on 23 March 2012.
Literature
1.
Hall MJ, Owings MF: 2000 National Hospital Discharge Survey: Advance Data From Vital and Health Statistics, No. 329. Hyattsville, Md. National Center for Health Statistics. 2002, No. 329
2.
Mangano DT: Perioperative cardiac morbidity. Anesthesiology. 1990, 72: 153-184. 10.1097/00000542-199001000-00025.CrossRefPubMed
3.
Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR, Gawande AA: An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008, 372: 139-144. 10.1016/S0140-6736(08)60878-8.CrossRefPubMed
4.
Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L: Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999, 100: 1043-1049. 10.1161/01.CIR.100.10.1043.CrossRefPubMed
5.
Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999, 341: 1789-1794. 10.1056/NEJM199912093412402.CrossRefPubMed
6.
Lindenauer PK, Fitzgerald J, Hoople N, Benjamin EM: The potential preventability of postoperative myocardial infarction: underuse of perioperative beta-adrenergic blockade. Arch Intern Med. 2004, 164: 762-766. 10.1001/archinte.164.7.762.CrossRefPubMed
7.
Nettleman MD, Banitt L, Barry W, Awan I, Gordon EE: Predictors of survival and the role of gender in postoperative myocardial infarction. Am J Med. 1997, 103: 357-362. 10.1016/S0002-9343(97)00162-9.CrossRefPubMed
8.
Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM: Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007, 116: 2634-2653. 10.1161/CIRCULATIONAHA.107.187397.CrossRefPubMed
9.
Chong CP, van Gaal WJ, Savige J, Lim WK: Cardiac injury and troponin testing after orthopaedic surgery. Injury. 2011, 42: 855-863. 10.1016/j.injury.2009.10.015.CrossRefPubMed
10.
Bursi F, Babuin L, Barbieri A, Politi L, Zennaro M, Grimaldi T, Rumolo A, Gargiulo M, Stella A, Modena MG, Jaffe AS: Vascular surgery patients: perioperative and long-term risk according to the ACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur Heart J. 2005, 26: 2448-2456. 10.1093/eurheartj/ehi430.CrossRefPubMed
11.
Landesberg G, Shatz V, Akopnik I, Wolf YG, Mayer M, Berlatzky Y, Weissman C, Mosseri M: Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol. 2003, 42: 1547-1554. 10.1016/j.jacc.2003.05.001.CrossRefPubMed
12.
Porto I, Selvanayagam JB, van Gaal WJ, Prati F, Cheng A, Channon K, Neubauer S, Banning AP: Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation. 2006, 114: 662-669. 10.1161/CIRCULATIONAHA.105.593210.CrossRefPubMed
13.
Chong CP, Lam QT, Ryan JE, Sinnappu RN, Lim WK: Incidence of post-operative troponin I rises and 1-year mortality after emergency orthopaedic surgery in older patients. Age Ageing. 2009, 38: 168-174.CrossRefPubMed
14.
Chong CP, van Gaal WJ, Ryan JE, Profitis K, Savige J, Lim WK: Does cardiology intervention improve mortality for post-operative troponin elevations after emergency orthopaedic-geriatric surgery? A randomised controlled study. Injury. 2012, 43: 1193-1198. 10.1016/j.injury.2012.03.034.CrossRefPubMed
15.
Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS: Perioperative myocardial infarction. Circulation. 2009, 119: 2936-2944. 10.1161/CIRCULATIONAHA.108.828228.CrossRefPubMed
16.
Landesberg G, Mosseri M, Zahger D, Wolf Y, Perouansky M, Anner H, Drenger B, Hasin Y, Berlatzky Y, Weissman C: Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia. J Am Coll Cardiol. 2001, 37: 1839-1845. 10.1016/S0735-1097(01)01265-7.CrossRefPubMed
17.
Feringa HH, Bax JJ, Boersma E, Kertai MD, Meij SH, Galal W, Schouten O, Thomson IR, Klootwijk P, van Sambeek MR, Klein J, Poldermans D: High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation. 2006, 114: I344-I349.CrossRefPubMed
18.
Fukumoto Y, Hiro T, Fujii T, Hashimoto G, Fujimura T, Yamada J, Okamura T, Matsuzaki M: Localized elevation of shear stress is related to coronary plaque rupture: a 3-dimensional intravascular ultrasound study with in-vivo color mapping of shear stress distribution. J Am Coll Cardiol. 2008, 51: 645-650. 10.1016/j.jacc.2007.10.030.CrossRefPubMed
19.
Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM: Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med. 1990, 323: 1781-1788. 10.1056/NEJM199012273232601.CrossRefPubMed
20.
Browner WS, Li J, Mangano DT: In-hospital and long-term mortality in male veterans following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA. 1992, 268: 228-232. 10.1001/jama.1992.03490020076034.CrossRefPubMed
21.
Frank SM, Beattie C, Christopherson R, Rock P, Parker S, Gottlieb SO: Perioperative rate-related silent myocardial ischemia and postoperative death. J Clin Anesth. 1990, 2: 326-331. 10.1016/0952-8180(90)90079-I.CrossRefPubMed
22.
Fleisher LA, Nelson AH, Rosenbaum SH: Postoperative myocardial ischemia: etiology of cardiac morbidity or manifestation of underlying disease?. J Clin Anesth. 1995, 7: 97-102. 10.1016/0952-8180(94)00030-8.CrossRefPubMed
23.
Landesberg G, Luria MH, Cotev S, Eidelman LA, Anner H, Mosseri M, Schechter D, Assaf J, Erel J, Berlatzky Y: Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery. Lancet. 1993, 341: 715-719. 10.1016/0140-6736(93)90486-Z.CrossRefPubMed
24.
Mangano DT, Hollenberg M, Fegert G, Meyer ML, London MJ, Tubau JF, Krupski WC: Perioperative myocardial ischemia in patients undergoing noncardiac surgery–I: Incidence and severity during the 4 day perioperative period. The Study of Perioperative Ischemia (SPI) Research Group. J Am Coll Cardiol. 1991, 17: 843-850. 10.1016/0735-1097(91)90863-5.CrossRefPubMed
25.
Rapp HJ, Rabethge S, Luiz T, Haux P: Perioperative ST-segment depression and troponin T release. Identification of patients with highest risk for myocardial damage. Acta Anaesthesiol Scand. 1999, 43: 124-129. 10.1034/j.1399-6576.1999.430202.x.CrossRefPubMed
26.
Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996, 335: 1713-1720. 10.1056/NEJM199612053352301.CrossRefPubMed
27.
Yang H, Raymer K, Butler R, Parlow J, Roberts R: The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J. 2006, 152: 983-990. 10.1016/j.ahj.2006.07.024.CrossRefPubMed
28.
Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, Norgaard P, Fruergaard K, Bestle M, Vedelsdal R, Miran A, Jacobsen J, Roed J, Mortensen MB, Jorgensen L, Jorgensen J, Rovsing ML, Petersen PL, Pott F, Haas M, Albret R, Nielsen LL, Johansson G, Stjernholm P, Molgaard Y, Foss NB, Elkjaer J, Dehlie B, Boysen K, Zaric D: Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ. 2006, 332: 1482-10.1136/bmj.332.7556.1482.CrossRefPubMedPubMedCentral
29.
Devereaux PJ, Beattie WS, Choi PT, Badner NH, Guyatt GH, Villar JC, Cina CS, Leslie K, Jacka MJ, Montori VM, Bhandari M, Avezum A, Cavalcanti AB, Giles JW, Schricker T, Yang H, Jakobsen CJ, Yusuf S: How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ. 2005, 331: 313-321. 10.1136/bmj.38503.623646.8F.CrossRefPubMedPubMedCentral
30.
Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P: Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008, 371: 1839-1847.CrossRefPubMed
31.
Hollenberg SM, Dellinger RP: Noncardiac surgery: postoperative arrhythmias. Crit Care Med. 2000, 28: N145-N150. 10.1097/00003246-200010001-00006.CrossRefPubMed
32.
Vaporciyan AA, Correa AM, Rice DC, Roth JA, Smythe WR, Swisher SG, Walsh GL, Putnam JB: Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg. 2004, 127: 779-786. 10.1016/j.jtcvs.2003.07.011.CrossRefPubMed
33.
Davis EM, Packard KA, Hilleman DE: Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers. Pharmacotherapy. 2010, 30: 749, 274e-318e.CrossRef
34.
Echahidi N, Pibarot P, O'Hara G, Mathieu P: Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008, 51: 793-801. 10.1016/j.jacc.2007.10.043.CrossRefPubMed
35.
Kaireviciute D, Aidietis A, Lip GY: Atrial fibrillation following cardiac surgery: clinical features and preventative strategies. Eur Heart J. 2009, 30: 410-425.CrossRefPubMed
36.
Mayson SE, Greenspon AJ, Adams S, Decaro MV, Sheth M, Weitz HH, Whellan DJ: The changing face of postoperative atrial fibrillation prevention: a review of current medical therapy. Cardiol Rev. 2007, 15: 231-241. 10.1097/CRD.0b013e31813e62bb.CrossRefPubMed
37.
38.
DiFrancesco D, Camm JA: Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004, 64: 1757-1765. 10.2165/00003495-200464160-00003.CrossRefPubMed
39.
Borer JS, Fox K, Jaillon P, Lerebours G: Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003, 107: 817-823. 10.1161/01.CIR.0000048143.25023.87.CrossRefPubMed
40.
Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, Thuillez C: Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006, 61: 127-137. 10.1111/j.1365-2125.2005.02544.x.CrossRefPubMed
41.
Manz M, Reuter M, Lauck G, Omran H, Jung W: A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003, 100: 149-155. 10.1159/000073933.CrossRefPubMed
42.
Camm AJ, Lau CP: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D. 2003, 4: 83-89. 10.2165/00126839-200304020-00001.CrossRefPubMed
43.
Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L: Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol. 2010, 99: 853-855. 10.1007/s00392-010-0208-9.CrossRefPubMed
44.
Shchukin Iu V, Vachev AN, Surkova EA, Germanov AV, Golovin EA, D'Iachkov VA: [The role of beta-adrenoblockers and If-inhibitor ivabradine in lowering of rate of development of cardiac complications after carotid endarterectomy]. Kardiologiia. 2008, 48: 56-59.PubMed
45.
Libby P, Aikawa M: Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002, 8: 1257-1262. 10.1038/nm1102-1257.CrossRefPubMed
46.
McFalls EO, Ward HB, Moritz TE, Apple FS, Goldman S, Pierpont G, Larsen GC, Hattler B, Shunk K, Littooy F, Santilli S, Rapp J, Thottapurathu L, Krupski W, Reda DJ, Henderson WG: Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP trial. Eur Heart J. 2008, 29: 394-401. 10.1093/eurheartj/ehm620.CrossRefPubMed
47.
Lee TH, Thomas EJ, Ludwig LE, Sacks DB, Johnson PA, Donaldson MC, Cook EF, Pedan A, Kuntz KM, Goldman L: Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery. Am J Cardiol. 1996, 77: 1031-1036. 10.1016/S0002-9149(96)00126-9.CrossRefPubMed
48.
Breslow MJ, Parker SD, Frank SM, Norris EJ, Yates H, Raff H, Rock P, Christopherson R, Rosenfeld BA, Beattie C: Determinants of catecholamine and cortisol responses to lower extremity revascularization. The PIRAT Study Group. Anesthesiology. 1993, 79: 1202-1209. 10.1097/00000542-199312000-00010.CrossRefPubMed
49.
Sametz W, Metzler H, Gries M, Porta S, Sadjak A, Supanz S, Juan H: Perioperative catecholamine changes in cardiac risk patients. Eur J Clin Invest. 1999, 29: 582-587. 10.1046/j.1365-2362.1999.00509.x.CrossRefPubMed
50.
Chernow B, Alexander HR, Smallridge RC, Thompson WR, Cook D, Beardsley D, Fink MP, Lake CR, Fletcher JR: Hormonal responses to graded surgical stress. Arch Intern Med. 1987, 147: 1273-1278. 10.1001/archinte.1987.00370070087013.CrossRefPubMed
51.
Parker SD, Breslow MJ, Frank SM, Rosenfeld BA, Norris EJ, Christopherson R, Rock P, Gottlieb SO, Raff H, Perler BA, Williams GM, Beattie C: Catecholamine and cortisol responses to lower extremity revascularization: correlation with outcome variables. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Crit Care Med. 1995, 23: 1954-1961. 10.1097/00003246-199512000-00003.CrossRefPubMed
52.
Rosenfeld BA, Faraday N, Campbell D, Dorman T, Clarkson K, Siedler A, Breslow MJ, Bell W: Perioperative platelet reactivity and the effects of clonidine. Anesthesiology. 1993, 79: 255-261. 10.1097/00000542-199308000-00010.CrossRefPubMed
53.
Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004, 110: 674-678. 10.1161/01.CIR.0000137828.06205.87.CrossRefPubMed
54.
Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A: Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009, 54: 2157-2163. 10.1016/j.jacc.2009.07.005.CrossRefPubMed
55.
Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM: Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA. 2004, 291: 2092-2099. 10.1001/jama.291.17.2092.CrossRefPubMed
56.
Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B: Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006, 105: 1260-1272. 10.1097/00000542-200612000-00027. quiz 1289-1290CrossRefPubMed
57.
Braunwald E: Biomarkers in heart failure. N Engl J Med. 2008, 358: 2148-2159. 10.1056/NEJMra0800239.CrossRefPubMed
58.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004, 350: 655-663. 10.1056/NEJMoa031994.CrossRefPubMed
59.
Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008, 358: 2107-2116. 10.1056/NEJMoa0707064.CrossRefPubMed
60.
de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001, 345: 1014-1021. 10.1056/NEJMoa011053.CrossRefPubMed
61.
Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM, Braunwald E: Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005, 294: 2866-2871. 10.1001/jama.294.22.2866.CrossRefPubMed
62.
Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E: Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007, 50: 205-214. 10.1016/j.jacc.2007.03.038.CrossRefPubMed
63.
Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, Zeller T, Sinning CR, Rupprecht HJ, Bickel C, Peetz D, Cambien F, Kempf T, Wollert KC, Benjamin EJ, Lackner KJ, Munzel TF, Tiret L, Vasan RS, Blankenberg S: Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J. 2010, 31: 3024-3031. 10.1093/eurheartj/ehq322.CrossRefPubMed
64.
Chong CP, Ryan JE, van Gaal WJ, Lam QT, Sinnappu RN, Burrell LM, Savige J, Lim WK: Usefulness of N-terminal pro-brain natriuretic peptide to predict postoperative cardiac complications and long-term mortality after emergency lower limb orthopedic surgery. Am J Cardiol. 2010, 106: 865-872. 10.1016/j.amjcard.2010.05.012.CrossRefPubMed
65.
Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E: Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012, 125: 233-240. 10.1161/CIRCULATIONAHA.111.063842.CrossRefPubMed
66.
Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med. 1998, 339: 321-328. 10.1056/NEJM199807303390507.CrossRefPubMed
67.
Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ: The clinical relevance of adrenomedullin: a promising profile?. Pharmacol Ther. 2004, 103: 179-201. 10.1016/j.pharmthera.2004.07.002.CrossRefPubMed
68.
Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM, Burnett JC: Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol. 1997, 273: R1392-R1399.PubMed
69.
Spieker LE, Noll G, Ruschitzka FT, Luscher TF: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?. J Am Coll Cardiol. 2001, 37: 1493-1505. 10.1016/S0735-1097(01)01210-4.CrossRefPubMed
70.
Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R: Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009, 53: 1783-1790. 10.1016/j.jacc.2009.01.057.CrossRefPubMed
71.
von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, Rozentryt P, Vassanelli C, Struck J, Banasiak W, Ponikowski P, Kremastinos D, Bergmann A, Morgenthaler NG, Anker SD: Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010, 12: 484-491. 10.1093/eurjhf/hfq031.CrossRefPubMed
72.
Jankowska EA, Filippatos GS, von Haehling S, Papassotiriou J, Morgenthaler NG, Cicoira M, Schefold JC, Rozentryt P, Ponikowska B, Doehner W, Banasiak W, Hartmann O, Struck J, Bergmann A, Anker SD, Ponikowski P: Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One. 2011, 6: e14506-10.1371/journal.pone.0014506.CrossRefPubMedPubMedCentral
73.
Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, Vuolteenaho O: Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004, 50: 1576-1588. 10.1373/clinchem.2004.032490.CrossRefPubMed
74.
Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S: Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes. Circulation. 2012, 125: 757-766. 10.1161/CIRCULATIONAHA.111.063487.CrossRefPubMed
75.
Pillarisett S, Alexander CW, Saxena U: Atherosclerosis – new targets and therapeutics. Curr Med Chem Cardiovasc Hematol Agents. 2004, 2: 327-334. 10.2174/1568016043356246.CrossRef
76.
Madjid M, Ali M, Willerson JT: Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Tex Heart Inst J. 2010, 37 (1): 25-39.PubMedPubMedCentral
77.
Tselepis AD, John CM: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating. Atheroscler Suppl. 2002, 3 (4): 57-68. 10.1016/S1567-5688(02)00045-4.CrossRefPubMed
78.
Mallat Z, Lambeau G, Tedgui A: Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010, 122: 2183-2200. 10.1161/CIRCULATIONAHA.110.936393.CrossRefPubMed
79.
Nijmeijer R, Meuwissen M, Krijnen PA, van der Wal A, Piek JJ, Visser CA, Hack CE, Niessen HW: Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction. Eur J Clin Invest. 2008, 38 (4): 205-210. 10.1111/j.1365-2362.2008.01933.x. doi:10.1111/j.1365-2362.2008.01933.xCrossRefPubMed
80.
Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H: Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol. 2000, 86 (7): 718-722. 10.1016/S0002-9149(00)01069-9.CrossRefPubMed
81.
Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H: Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 1999, 100 (12): 1280-1284. 10.1161/01.CIR.100.12.1280.CrossRefPubMed
82.
Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, Chen JH: Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J. 2003, 24 (20): 1824-1832. 10.1016/j.ehj.2003.07.003.CrossRefPubMed
83.
Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM: Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-NORFOLK study. Arterioscler Thromb Vasc Biol. 2007, 27 (5): 1177-1183. 10.1161/ATVBAHA.107.139352.CrossRefPubMed
84.
Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D: Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009, 30 (22): 2742-2748. 10.1093/eurheartj/ehp302.CrossRefPubMed
85.
Eggen DA, Strong JP, McGill HC: Coronary calcification. Relationship to clinically significant coronary lesions and race, sex, and topographic distribution. Circulation. 1965, 32: 948-955. 10.1161/01.CIR.32.6.948.CrossRefPubMed
86.
Hoff JA, Chomka EV, Krainik AJ, Daviglus M, Rich S, Kondos GT: Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults. Am J Cardiol. 2001, 87: 1335-1339. 10.1016/S0002-9149(01)01548-X.CrossRefPubMed
87.
Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA, Sheedy IP, Peyser PA, Schwartz RS: Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 2001, 104: 412-417. 10.1161/hc2901.093112.CrossRefPubMed
88.
Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM: Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol. 2000, 86: 495-498. 10.1016/S0002-9149(00)01000-6.CrossRefPubMed
89.
Carr JJ, Crouse JR, Goff DC, D'Agostino RB, Peterson NP, Burke GL: Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. AJR Am J Roentgenol. 2000, 174: 915-921. 10.2214/ajr.174.4.1740915.CrossRefPubMed
90.
Callister TQ, Cooil B, Raya SP, Lippolis NJ, Russo DJ, Raggi P: Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology. 1998, 208: 807-814. 10.1148/radiology.208.3.9722864.CrossRefPubMed
91.
van der Bijl N, de Bruin PW, Geleijns J, Bax JJ, Schuijf JD, de Roos A, Kroft LJM: Assessment of coronary artery calcium by using volumetric 320-row multi-detector computed tomography: comparison of 0.5 mm with 3.0 mm slice reconstructions. Int J Cardiovasc Imaging. 2010, 26: 473-482. 10.1007/s10554-010-9581-8.CrossRefPubMedPubMedCentral
Metadata
Title
Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarction: study protocol for a randomized controlled trial
Authors
Nima Rudd
Ivan Subiakto
Muhammad Asrar ul Haq
Vivek Mutha
William J Van Gaal
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Trials / Issue 1/2014
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-15-352

Other articles of this Issue 1/2014

Trials 1/2014 Go to the issue

Research

Complex realities: community engagement for a paediatric randomized controlled malaria vaccine trial in Kilifi, Kenya

Study protocol

A pilot study of respiratory muscle training to improve cough effectiveness and reduce the incidence of pneumonia in acute stroke: study protocol for a randomized controlled trial

Study protocol

Staged transthoracic approach to persistent atrial fibrillation (TOP-AF): study protocol for a randomized trial

Study protocol

Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial

Study protocol

The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled trial

Study protocol

Photodynamic therapy as a novel treatment for halitosis in adolescents: study protocol for a randomized controlled trial